Cephalon Myotrophin
Executive Summary
Company expects data analysis for its pivotal trials in amyotrophic lateral sclerosis to be complete in the first quarter of 1995. A forecasted NDA filing date reported in "The Pink Sheet" (May 9, T&G-2) is incorrect